ArticleInternal and emergency medicine2026
Phenobarbital monotherapy vs benzodiazepines for alcohol withdrawal syndrome: a multicenter propensity-matched comparative effectiveness study.
Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcohol withdrawal syndrome (AWS) is a common and potentially severe condition among hospitalized patients, with complications such as seizures and delirium tremens contributing to significant morbidity and healthcare utilization. Although benzodiazepines remain the recommended first-line therapy, increasing interest has emerged in phenobarbital as an alternative pharmacologic strategy. However, large comparative studies evaluating phenobarbital monotherapy relative to benzodiazepines remain limited. Using the TriNetX Global Collaborative Network, we identified hospitalized adults with AWS treated with phenobarbital monotherapy or benzodiazepines. Patients receiving phenobarbital were required to have no concurrent benzodiazepine exposure. Clinical outcomes were compared after 1:1 propensity score matching for demographic characteristics, comorbid conditions, psychiatric and substance use disorders, medication exposures, and laboratory values. Effect estimates were reported as relative risks (RRs) with 95% confidence intervals. After propensity score matching, 4712 patients were included in each cohort. Admission to a critical care setting was significantly higher among patients treated with phenobarbital (RR 1.85, 95% CI 1.66-2.06; p < 0.001). There were no significant differences in mechanical ventilation (RR 0.82, 95% CI 0.66-1.03; p = 0.08), vasopressor use (RR 0.83, 95% CI 0.47-1.46; p = 0.46), aspiration pneumonitis (RR 0.73, 95% CI 0.51-1.04; p = 0.075), or in-hospital mortality (RR 0.74, 95% CI 0.53-1.05; p = 0.092) among both groups. Phenobarbital use was associated with significantly lower risks of seizures (RR 0.70, 95% CI 0.58-0.85; p < 0.001) and delirium tremens (RR 0.52, 95% CI 0.41-0.65; p < 0.001), as well as a lower risk of escalation to additional sedative therapy (RR 0.89, 95% CI 0.84-0.94; p < 0.001).Phenobarbital monotherapy was associated with significantly lower risks of seizures, delirium tremens, and escalation to additional sedative therapy compared with benzodiazepines. Despite a higher risk of critical care utilization, there were no significant differences in mechanical ventilation, vasopressor use, aspiration pneumonitis, or in-hospital mortality. These findings support phenobarbital as a viable alternative treatment strategy for hospitalized patients with alcohol withdrawal syndrome.
Indexed as
Identifiers
42260228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.